We invite you to explore the latest partnering opportunities from Commercial Healthcare Partners below.
5 Jul 2016
arGentis receives U.S Patent for Arthritis Treatment
Memphis, TN—arGentis Pharmaceuticals, LLC announced today the issuance
of EU patent No. 2,286,218 for a single nucleotide polymorphism (SNP)
associated with resistance to immune tolerance. This SNP and will be
used as a biomarker to identify patients that will respond to arGentis’
treatment for scleroderma.
The research supporting this patent
was conducted at the University of Tennessee Health Science Center in
Memphis, Tennessee and is licensed by arGentis™ from the University of
Tennessee Research Foundation. This patent grants the use of this
biomarker in the EU and is based upon the research of doctors Arnold
Postlethwaite, Andrew Kang, and Weikuan Gu at the University of
Tennessee Health Science Center in Memphis Tennessee.
is a complex and deadly autoimmune disease that attacks the naturally
incurring type 1 collagen in the body. Collagen build up results in
widespread connective tissue fibrosis and vascular injury leading to
organ system failures. The arGentis treatment (ARG201) is
targeted to treat diffuse systemic scleroderma (dSSc) which is the most
serious type of Scleroderma and always leads to some internal organ
involvement. It is a rare disease with a relative poor prognosis. Women
are 4 to 5 times more likely than men to develop dSSc. Progressive
pulmonary fibrosis, pulmonary hypertension, severe gastrointestinal
involvement, and scleroderma heart disease are the main causes of death.
Mortality rates are 5 to 8 times greater than the general population.
Pharmaceuticals, located in Tennessee was established in 2007 to
develop pharmaceuticals that address unmet medical needs. The mission of
arGentis™ is to develop and commercialize treatments to improve the
health and quality of life of the targeted patient groups and provide a
fair return to our investors.
The current focus is on autoimmune diseases treated primarily by Rheumatologists.
For more information, contact:
Tom Davis, President and CEO, arGentis Pharmaceuticals, LLC
Return to Press Releases